Can a molecule that boosts cell energy reach the brain in Alzheimer's?
NCT ID NCT05040321
First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early-stage study tests whether a daily pill called MIB-626 can enter the brain and affect aging-related pathways in people with mild Alzheimer's disease. Researchers will measure the drug and its byproducts in spinal fluid and use advanced brain scans to see if it boosts NAD, a key energy molecule. The study involves 22 participants aged 55 to 85 with confirmed Alzheimer's pathology. The goal is to gather evidence for future, larger trials, not to treat the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115-0000, United States
Conditions
Explore the condition pages connected to this study.